Diamyd Medical Ab (DMYDF) Inactive USPTO patents

Utility

Preventing and Treating Hypoglycemia

6 Jul 23

The present invention relates to Gamma-amino butyric acid, optionally in combination with a Positive Allosteric Modulator of a GABA-receptor, for use in a method for preventing, or reducing risk of, hypoglycemia in a subject.

Daniel ESPES, Per-Ola CARLSSON

Filed: 7 Aug 20

Utility

Formulation of gamma-aminobutyric acid

2 May 23

The present invention relates to an oral dosage form comprising gamma-aminobutyric acid (GABA) and pharmaceutically acceptable excipients, wherein 100% of the GABA is released within 0.25-5 hours in 0.01 M HCl at 37° C. in a USP dissolution apparatus 2.

Anton Lindqvist, Ulf Hannelius

Filed: 24 Aug 18

Utility

kuzfu7pvyr3qvbr0v8it9 onxab96knjctfz6o3n59xcs0ujqlwo

6 Jan 22

The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years.

Anders ESSEN-MÖLLER, Johnny LUDVIGSSON

Filed: 26 Aug 21

Utility

guf5oq9ujzuzk5silk2z

13 May 21

The present invention relates to an oral dosage form comprising gamma-aminobutyric acid (GABA) and pharmaceutically acceptable excipients, wherein 100% of the GABA is released within 0.25-5 hours in 0.01 M HCl at 37° C. in a USP dissolution apparatus 2.

Anton LINDQVIST, Ulf HANNELIUS

Filed: 24 Aug 18

Utility

5zscvq62ddalt4dans087hm33ou1j4

22 Apr 21

The present invention relates to methods for identifying patients a subject at risk of developing an autoimmune or inflammatory disorder, as well as methods of prevention of development of an autoimmune or inflammatory disorder, comprising administering GABA, or a GABA receptor agonist, to a subject so identified.

Bryndis BIRNIR, Ulf HANNELIUS, Anton LINDQVIST

Filed: 25 Feb 19

Utility

h9qu7x1nzrucd4g595i0s95k02hfiek4t5pzny

18 Mar 21

The present invention relates to a method for treatment or prevention of an autoimmune disease in a patient, comprising: (a) Determining the HLA genotype of the patient; and (b) Subjecting the patient to a treatment regimen based on said genotype.

Anders ESSEN-MÖLLER

Filed: 10 Sep 18

Utility

oehldrqhvf99culh2wxwtjp2gsm49nru19qmozz27jpyodgryakiqj7kwk

4 Mar 21

The invention relates to a method for assessing the efficacy of an immunotherapy comprising administration of GAD to a patient, comprising the following steps: measuring at least one of GADA IgG subclass distribution; GADA levels; distribution of cytokines secreted from lymphocytes; and lymphocyte proliferation in presence of GAD or CD3/CD28 beads; in a first blood, plasma or serum sample obtained from said patient at a first point in time and in a second blood, plasma or serum sample obtained from said patient at a later point in time; and comparing the so obtained measurements.

Johnny LUDVIGSSON, Rosaura CASAS, Ulf HANNELIUS, Anton LINDQVIST, Anders ESSEN-MÖLLLER

Filed: 6 Sep 18

Utility

7bm57hcbvysjzmdlqox s2t97

9 Dec 20

The present invention relates to methods for treatment or prevention of disorders caused influenced by dysfunction of β cells by administering to said patient a compound selected from the group consisting of GABAA receptor agonists.

Bryndis BIRNIR, Ulf HANNELIUS, Anton LINDQVIST

Filed: 20 Feb 19

Utility

9hi6a96nz0f7un43wpvcbgds3bnrdhqhzdev58f499o09

18 Nov 20

The present invention relates to the use of at least two autoantigens specific to an autoimmune disease for treatment of said disease.

Ulf HANNELIUS, Anders ESSEN-MÖLLER, Anton LINDQVIST

Filed: 4 Feb 19

Utility

bdqgtxr0aqpcpintpd5kkspvsm4mn0cfjhcikbn1rlh6dy3rt

6 May 20

Provided herein, among other things, is a method for prevention and/or treatment of an autoimmune disease.

Anders ESSEN-MÖLLER, Johnny LUDVIGSSON

Filed: 9 Sep 19

Utility

5szi0jthpcs4jco2 wk6dxq

27 Nov 19

The present invention relates to a method for in vitro cultivation of hematopoietic and/or mesenchymal cells, wherein said cells are cultivated in a cultivation medium comprising gamma-aminobutyric acid (GABA) or a GABA receptor agonist, to cells obtained by such a method and therapeutic use of such cells in methods of treatment of autoimmune, inflammatory or allergic disorder.

Anders ESSEN-MÖLLER

Filed: 22 Aug 16